You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 6,862,890


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,862,890
Title: Process for production of nanoparticles and microparticles by spray freezing into liquid
Abstract:The present invention provides a system and a method for the production of microparticles and nanoparticles of materials that can be dissolved. The system and method of the present invention provide quicker freezing times, which in turn produces a more uniform distribution of particle sizes, smaller particles, particles with increased porosity and a more intimate mixing of the particle components. The system and method of the present invention also produce particles with greater surface area than conventional methods. One form of the present invention provides a method for the preparation of particles. An effective ingredient is mixed with water, one or more solvents, or a combination thereof, and the resulting mixture is sprayed through an insulating nozzle located at or below the level of a cryogenic liquid. The spray generates frozen particles.
Inventor(s): Williams, III; Robert O. (Austin, TX), Johnston; Keith P. (Austin, TX), Young; Timothy J. (Midland, MI), Rogers; True L. (Austin, TX), Barron; Melisa K. (Conroe, TX), Yu; Zhongshui (Austin, TX), Hu; Jiahui (Austin, TX)
Assignee: Board of Regents, University of Texas System (Austin, TX)
Application Number:10/062,648
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,862,890
Patent Claims:1. A system for preparing particles comprising: a solution source comprising an effective ingredient; a vessel containing a cryogenic liquid selected from the group consisting of carbon dioxide, nitrogen, ethane, propane, helium, argon, or isopentane; and an insulating nozzle having an end and a tip, wherein the end of the insulating nozzle is connected to the solution source and the tip is placed at or below the level of the cryogenic liquid.

2. The system recited in claim 1, wherein the effective ingredient is a pharmaceutical.

3. The system recited in claim 2, wherein the effective ingredient is chosen from the group consisting of proteins, peptides, albuterol sulfate, terbutaline sulfate, diphenhydramine hydrochloride, chlorpheniramine maleate, loratidine hydrochloride, fexofenadine hydrochloride, phenylbutazone, nifedipine, carbamazepine, naproxen, cyclosporin, betamethosone, danazol, dexamethasone, prednisone, hydrocortisone, 17 beta-estradiol, ketoconazole, mefenamic acid, beclomethasone, alprazolam, midazolam, miconazole, ibuprofen, ketoprofen, prednisolone, methylprednisone, phenytoin, testosterone, flunisolide, diflunisal, budesonide, fluticasone; insulin, glucagon-like peptide, C-Peptide, erythropoietin, calcitonin, human growth hormone, leutenizing hormone, prolactin, adrenocorticotropic hormone, leuprolide, interferon alpha-2b, interferon beta-1a, sargramostim, aldesleukin, interferon alpha-2a, interferon alpha-n3alpha,-proteinase inhibitor; etidronate, nafarelin, chorionic gonadotropin, prostaglandin E2, epoprostenol, acarbose, metformin, or desmopressin, cyclodextrin, antibiotics; and the pharmacologically acceptable organic and inorganic salts or metal complex thereof.

4. The system recited in claim 1, wherein the solution source further comprises water, at least one organic solvent, or a combination thereof.

5. The system recited in claim 4, wherein the organic solvent is selected from the group consisting of water miscible solvents and non-water miscibl solvents.

6. The system recited in claim 5, wherein the organic solvent is elected from the group consisting of ethanol, methanol, tetrahydrofuran, acetonitril acetone, tert-butyl alcohol, dimethyl sulfoxide, N,N-dimethyl formamide, diethyl ether, methylene chloride, ethyl acetate, isopropyl acetate, butyl acetate, propyl acetate, toluene, hexanes, heptane, pentane, and combinations thereof.

7. The system recited in claim 1, wherein the solution source further comprises an excipient, an adjuvant, an absorption enhancer, a release-rate controlling polymer, a stability enhancer, or combinations thereof.

8. The system recited in claim 1, wherein the tip of the insulating nozzle has a diameter of between 1 micron and 1 centimeter.

9. A method for spray freezing comprising: mixing an effective ingredient with a solution agent; spraying the effective ingredient-solution agent mixture through an insulating nozzle located at or below the level of a cryogenic liquid, wherein the spray rapidly generates frozen particles having a size range of 10nm to 10 microns.

10. The method recited in claim 9, wherein the solution agent is selected from water, at least one organic solvent, or a combination thereof.

11. The method recited in claim 9, further comprising collecting the frozen particles.

12. The method recited in claim 9, wherein the effective ingredient is a water soluble pharmaceutical or a poorly water soluble pharmaceutical.

13. The method recited in claim 9, further comprising drying the frozen particles to substantially remove the water.

14. The method recited in claim 13, wherein the frozen particles are dried in a fluidized bed with a gas cooled to below the melting point of the frozen particles.

Details for Patent 6,862,890

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 01/15/1974 ⤷  Try a Trial 2021-01-30
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 12/27/1984 ⤷  Try a Trial 2021-01-30
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/15/1985 ⤷  Try a Trial 2021-01-30
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 02/16/1990 ⤷  Try a Trial 2021-01-30
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 03/26/1974 ⤷  Try a Trial 2021-01-30
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 03/05/1973 ⤷  Try a Trial 2021-01-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.